Kristy Huang
Research Subjects
Kristy Huang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alopi Patel
Department of Anesthesiology and Perioperative Medicine, Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ
1 shared publication - Ami Shah
Department of Pharmacy, Mount Sinai Morningside Medical Center, New York, NY; Department of Cardiothoracic Surgery and Critical Care, Mount Sinai Morningside Medical Center, New York, NY
1 shared publication - Andras Farkas
Optimum Dosing Strategies, Bloomingdale, NJ, USA
1 shared publication Anthony Apigo
Department of Anesthesiology, Perioperative and Pain Medicine, Mount Sinai Morningside Medical Center, New York, NY
1 shared publication- Arsheena Yassin
Robert Wood Johnson University Hospital
1 shared publication Christine Stavropoulos
Icahn School of Medicine at Mount Sinai St Luke’s and West Hospitals, New York, NY
1 shared publication
Latest Publications
- 3 October 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 183-188
Perioperative Implementation of Low-Dose Pregabalin in an Enhanced Recovery After Cardiac Surgery Protocol: A Pre-Post Observational Study
- 3 October 2023
- Published by Elsevier in Journal of Cardiothoracic and Vascular Anesthesia
- Vol. 38 (1) , 183-188
Perioperative Implementation of Low-Dose Pregabalin in an Enhanced Recovery After Cardiac Surgery Protocol: A Pre-Post Observational Study
- Open Access
- 1 November 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S716-S717
1255. External Validation and Systematic Quantification of the Predictive Performance of Carbapenem Resistant Enterobacterales Risk Prediction Models in Hospitalized Patients
Accurately predicting the presence of a carbapenem resistant enterobacterales (CRE) in hospitalized patients presents itself as an opportunity that would support timely initiation of CRE active agents. The aim of this study is to determine how reliably the existing risk prediction models identify patients likely to require empiric anti-CRE treatment, preliminary results of which are presented herein. A systematic search identified all existing CRE prediction models for validation in our patient population. Medical records of hospitalized patients within the Mount Sinai Health System in New York were subsequently reviewed. Data was gathered on model predictors, baseline demographics, clinical information, microbiology results, antibiotic utilization history and index infection. Besides calculating the AUROC, the main outcome of our study was to establish optimal prediction score cutoffs and false positive rates (FPR) where corresponding model performance maintains a false negative rate (FNR) of < 10%, < 20% and < 30%, respectively. 12 models were retained for validation. We identified 106 patients, 41 of which were treated for a CRE infection. Previous admission, organ transplantation, CKD, infection type, and carbapenem use were baseline variables that significantly differed between the groups treated for a CRE or non-CRE related infection (Table 1). The models ability to discriminate varied as evidenced by the AUROC range of 0.5 to 0.77 (Figure 1), suggesting the Seligmen et al. model as the overall best. When evaluated at the pre-specified FNR intervals of < 10%, < 20% and < 30%, the model by Lodise et al., Seligman et al., and Vazquez-Guillamet et al. produced the best FPR, respectively (Table 2). Table 1. Baseline characchteristics Table 2. Model Performance Figure 1. AUROCs Discriminative ability of the risk prediction models showed varying performance. The model by Lodise et al. appears to be most useful when a low risk level is deemed acceptable for failure rate, while at a moderate to high risk of missing a CRE case (20% and 30% FNR), the methods by Seligman and Vazquez-Guillamet et al. are most desirable as they minimize the chance of over-treatment. Additional work to increase sample size and to evaluate the models inter-rater reliability is currently on going. All Authors: No reported disclosures
- 1 November 2021
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (Supplement) , S716-S717
Open Access1255. External Validation and Systematic Quantification of the Predictive Performance of Carbapenem Resistant Enterobacterales Risk Prediction Models in Hospitalized Patients
Accurately predicting the presence of a carbapenem resistant enterobacterales (CRE) in hospitalized patients presents itself as an opportunity that would support timely initiation of CRE active agents. The aim of this study is to determine how reliably the existing risk prediction models identify patients likely to require empiric anti-CRE treatment, preliminary results of which are presented herein. A systematic search identified all existing CRE prediction models for validation in our patient population. Medical records of hospitalized patients within the Mount Sinai Health System in New York were subsequently reviewed. Data was gathered on model predictors, baseline demographics, clinical information, microbiology results, antibiotic utilization history and index infection. Besides calculating the AUROC, the main outcome of our study was to establish optimal prediction score cutoffs and false positive rates (FPR) where corresponding model performance maintains a false negative rate (FNR) of < 10%, < 20% and < 30%, respectively. 12 models were retained for validation. We identified 106 patients, 41 of which were treated for a CRE infection. Previous admission, organ transplantation, CKD, infection type, and carbapenem use were baseline variables that significantly differed between the groups treated for a CRE or non-CRE related infection (Table 1). The models ability to discriminate varied as evidenced by the AUROC range of 0.5 to 0.77 (Figure 1), suggesting the Seligmen et al. model as the overall best. When evaluated at the pre-specified FNR intervals of < 10%, < 20% and < 30%, the model by Lodise et al., Seligman et al., and Vazquez-Guillamet et al. produced the best FPR, respectively (Table 2). Table 1. Baseline characchteristics Table 2. Model Performance Figure 1. AUROCs Discriminative ability of the risk prediction models showed varying performance. The model by Lodise et al. appears to be most useful when a low risk level is deemed acceptable for failure rate, while at a moderate to high risk of missing a CRE case (20% and 30% FNR), the methods by Seligman and Vazquez-Guillamet et al. are most desirable as they minimize the chance of over-treatment. Additional work to increase sample size and to evaluate the models inter-rater reliability is currently on going. All Authors: No reported disclosures